Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): How can we improve outcomes in the near future?

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1490-1495

  Phillips, Gordon L ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic; Improve outcomes; Myelodysplastic; Transplantation

Indexed keywords

AZACITIDINE; BUSULFAN; CLOFARABINE; CYCLOPHOSPHAMIDE; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; COMORBIDITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HUMAN; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PATIENT REFERRAL; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84868212496     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.004     Document Type: Review

References (36)

1. Gyurkocza B., Rezvani A., Storb R.F. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010, 3(June (3)):285-299.
2. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363(November (22)):2091-2101.
3. Bacher U., Talano J.A., Bishop M.R. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant 2012, 18(January (1 Suppl.)):S62-S73.
4. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117(February (8)):2307-2318.
5. Appelbaum F.R. Optimising the conditioning regimen for acute myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22(December (4)):543-550.
6. Ringdén O., Karlsson H., Olsson R., et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147(December):614-633.
7. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant (advanced online publication) 30 April 2012.
8. Röllig C., Bornhäuser M., Thiede C., et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011, 29(July (20)):2758-2765.
9. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301(June (22)):2349-2361.
10. Xu F., Deeg H.J. Current status of allogeneic hematopoietic cell transplantation for MDS. Curr Pharm Des 2012, 18(22):3215-3221.
11. Cornelissen J.J., Breems D., van Putten W.L., et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 2012, 30(June (17)):2140-2146.
12. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25(September (27)):4246-4254.
13. Ballen K.K., Koreth J., Chen Y.B., et al. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012, 119(March (9)):1972-1980.
14. Gupta V., Tallman M.S., He W., et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010, 116(September (11)):1839-1848.
15. Estey E., de Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109(February (4)):1395-1400.
16. Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977, 49(April (4)):511-533.
17. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011, 29(March (9)):1190-1197.
18. Tallman M.S., Rowlings P.A., Milone G., et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000, 96(August (4)):1254-1258.
19. Guzman M.L., Rossi R.M., Neelakantan S., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110(December (13)):4427-4435.
20. Clift R.A., Buckner F.R., Appelbaum K.M., et al. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 1998, 92(August (4)):1455-1456.
21. Wong J.W.C., Forman S., Somlo G., et al. Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys 2012, (May). [Epub ahead of print].
22. Deeg H.J. Transplantation conditioning regimens: can we say it better?. Biol Blood Marrow Transplant 2009, 15(June (6)):653-655.
23. Ciurea S.O., Andersson B.S. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15(May (5)):523-536.
24. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. Busulfan and fludarabine (i.v, Bu-Flu) compares favorably with i.v. Busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14(June (6)):672-684.
25. Alatrash G., de Lima M., Hamerschlak N., et al. Myeloablative reduced-toxicity i.v, Busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011, 17(October (10)):1490-1496.
26. Magenau J., Tobai H., Pawarode A., et al. Clofarabine and Busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 2011, 118(October (15)):4258-4264.
27. Nemecek E.R., Guthrie K.A., Sorror M.L., et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 2011, 17(March (3)):341-350.
28. Russell J.A., Irish W., Balogh A., et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous Busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010, 16:509-514.
29. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114(November (19)):4293-4299.
30. Velardi A., Ruggeri L., Mancusi A. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol 2012, 19(July (4)):319-323.
31. Elmaagacli A.H., Steckel N.K., Koldehoff M., et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011, 4(August):1402-1412.
32. Roddie C., Peggs K.S. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011, 11(April (4)):473-487.
33. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115(May (9)):1899-1905.
34. Breems D.A., van Putten W.L., Huigens P.C., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23(March (9)):1969-1978.
35. Duval M., Klein J.P., Wensheng H., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010, 28(August (23)):3730-3738.
36. Paun O., Lazarus H.M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission: have the indications changed?. Curr Opin Hematol 2012, 19(March (2)):95-101.